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Uric Acid Levels Are Relevant in Patients With Stroke
Treated With Thrombolysis
Sergio Amaro, MD; Xabier Urra, MD, PhD; Manuel Go´mez-Choco, MD; Víctor Obach, MD;
A´ lvaro Cervera, MD, PhD; Martha Vargas, PhD; Ferran Torres, MD, PhD; Jose Rios, BSc;
Anna M. Planas, PhD; A´ ngel Chamorro, MD, PhD
Background and Purpose—Uric acid (UA) is a neuroprotective antioxidant that improves the benefits of alteplase in
experimental ischemia. However, it is unknown whether endogenous UA also influences the response to thrombolysis
in patients with stroke.
Methods—A total of 317 consecutive patients treated with thrombolysis were included in a prospective stroke registry.
Demographics, laboratory data, neurological course, and infarction volume were prospectively collected. Excellent
outcome was defined as achieving a modified Rankin Scale score 2 at 90 days. Binary and ordinal logistic regression
models were used to analyze modified Rankin Scale score at 90 days.
Results—UA levels were significantly higher in patients with an excellent outcome than in patients with a poor outcome
(5.82 [1.39] versus 5.42 [1.81], P0.029). In multivariate models, increased UA levels (OR, 1.23; 95% CI, 1.03 to 1.49;
P0.025) were associated with an excellent outcome and with an increased risk of shifting to a better category across
the modified Rankin Scale (OR, 1.19; 95% CI, 1.04 to 1.38; P0.014) independently of the effect of confounders. The
levels of UA and the volume of final infarction were inversely correlated (r0.216, P0.001) and the inverse
correlation remained after adjustment for age, sex, and baseline National Institutes of Health Stroke Scale score (t
value2.54, P0.01). Significantly lower UA levels were found in patients with malignant middle cerebral artery
infarction and parenchymal hemorrhage postthrombolysis.
Conclusions—Increased UA serum levels are associated with better outcome in patients with stroke treated with
reperfusion therapies. These results support the assessment of the potential neuroprotective role of the exogenous
administration of UA in patients with stroke treated with thrombolysis. (Stroke. 2011;42[suppl 1]:S28-S32.)
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Uric acid (UA) is the end product of purine nucleotides,which are principal constituents of DNA, RNA, and
cellular energy stores. In humans, the concentration of UA is
higher than in most animals suggesting it may represent an
evolutionary advantage owing to its antioxidant properties.1
These properties include scavenging of hydroxyl radicals,
hydrogen peroxide, and peroxynitrite; suppression of the
Fenton reaction; chelation of transition metals; and preven-
tion of lipid peroxidation.2 UA could also have proinflamma-
tory effects such as stimulation of the synthesis of monocyte
chemoattractant protein-1 and increased production by mono-
cytes of interleukin-l, interleukin-6, and tumor necrosis
factor-.3
The administration of UA is neuroprotective in rats after
transient brain ischemia,4 and the benefit is additive to the
protection provided by alteplase.5 The relevance of UA levels
in patients with cardiovascular disease or stroke is conflict-
ing.6 Some studies showed an association between higher UA
and increased cardiovascular mortality,7,8 whereas others9,10
suggested that the apparent worse outcome in hyperuricemic
patients was confounded by the effects of more prevalent or
uncontrolled risk factors. In patients with acute stroke, higher
UA levels have been described in association with im-
proved11 or worse functional outcome.12–14 The generation of
UA is increased in the ischemic brain, although there is a
gradual exhaustion of the antioxidant capacity that has been
correlated with higher lesion volume and neurological im-
pairment in stroke.15 These clashing results could reflect the
variable timing of UA assessment in these studies, the
inconsistent definition of outcome, the uneven adjustment of
comorbidity or initial stroke severity, and the variable use of
therapeutic agents.
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The relevance of UA levels in patients with stroke treated
with thrombolytic therapy is unknown and this question
deserves consideration because the antioxidant capacity of
UA could be particularly beneficial in situations of enhanced
oxidative-mediated reperfusion injury. In this study, we
investigated the association between endogenous UA levels
and clinical and radiological outcomes in a consecutive series
of patients with stroke treated with thrombolysis.
Methods
Patients
A total of 317 consecutive patients aged 18 years treated with
intravenous or endovascular thrombolysis between January 2002 and
January 2010 were included in a prospective stroke registry. Demo-
graphics, including history of symptomatic cardiovascular disease
and prevalence of vascular risk factors, and radiological, clinical, and
laboratory data, were prospectively collected, and the neurological
function was assessed daily by stroke neurologists using the National
Institutes of Health Stroke Scale (NIHSS) from admission to hospital
discharge. Functional outcome was assessed with the modified
Rankin Scale (mRS) and NIHSS score at Day 90. Diagnostic tests
were performed to determine the cause of stroke as lacunar,
atherothrombotic, cardioembolic, undetermined, or other specific
causes. All patients had conventional laboratory tests including the
assessment of UA levels in fasting blood samples obtained within a
median (interquartile range) 24 (17 to 42) hours of stroke onset using
standard laboratory procedures with urate oxidase reagent on a Dax
analyzer (Bayer-Technichon) with an interassay coefficient of vari-
ation 3% to 5%.
A brain CT scan was performed before thrombolytic therapy and
repeated at 24 (12) hours or whenever it was required in patients
with worsening stroke (at least 4-point increment in the NIHSS
score). Once a brain CT scan ruled out the presence of hemorrhagic
stroke, intravenous thrombolysis was administered within the first 3
hours of stroke onset from January 2002 to October 2008 and within
4 to 5 hours after October 2008 (n277). From October 2008 to
January 2010, endovascular thrombolysis was used if intravenous
thrombolysis was contraindicated (n13) or as a rescue therapy for
occlusions resistant to intravenous thrombolysis (n27). Infarct
volume was measured on the second CT scan using the brain maps
of Gado, Hanaway, and Frank16 by investigators blinded to clinical
outcome and UA levels. Hemorrhagic transformation on CT scan
described any presence of blood regardless of symptoms and was
classified according to the European Cooperative Acute Stroke Study
criteria as hemorrhagic infarction (HI) and parenchymal hematoma
(PH) Types 1 and 2.17 Symptomatic intracerebral hemorrhage
defined those bleedings associated with at least a 4-point increment
in the NIHSS score. Malignant middle cerebral artery (MCA)
infarction was defined as lesions that occupied at least two thirds of
the MCA territory with mass effect. Excellent outcome was defined
Table 1. Main Traits of the Study Population According to Clinical Outcome at Day 90
mRS 0 to 1
(n101)
mRS 2 to 3
(n103)
mRS 4 to 6
(n113) P *
Demographics and risk factors
Males, no. (%) 66 (65.3) 63 (61.2) 48 (42.5) 0.020
Age, years, mean (SD) 68 (13.3) 71 (11.7) 76 (10.3) 0.000
Previous stroke, no. (%) 8 (8) 18 (18) 17 (15) 0.043
Hypertension, no. (%) 66 (65) 67 (65) 74 (66) 0.990
Diabetes, no. (%) 16 (16) 25 (24) 37 (33) 0.013
Coronary heart disease, no. (%) 18 (18) 18 (18) 20 (18) 0.960
Dyslipidemia, no. (%) 36 (36) 45 (44) 39 (35) 0.579
Smokers, no. (%) 40 (40) 40 (39) 32 (28) 0.276
Atrial fibrillation, no. (%) 19 (19) 67 (66) 63 (57) 0.000
Prior mRS 0 to 1, no. (%) 94 (93) 67 (66) 63 (57) 0.000
Baseline parameters
Baseline NIHSS, median (IQR) 6 (3–11) 9 (6–17) 18 (13–21) 0.000
Glucose, mg/dL, median (IQR) 119 (106–145) 128 (109–158) 128 (110–149) 0.114
Systolic blood pressure, mm Hg,
median (IQR)
155 (142–170) 155 (138–166) 151 (139–166) 0.422
UA levels, mg/dL, mean (SD) 5.8 (1.39) 5.6 (1.73) 5.2 (1.86) 0.029
Time of UA measurement since
stroke onset, median (IQR)
22 (17–40) 24 (16–43) 25 (18–44) 0.198
Treatment type, no. (%) 0.780
IVT 90 (89) 95 (92) 92 (81)
IVT-EVT 7 (7) 4 (4) 16 (14)
EVT 4 (4) 4 (4) 5 (4)
Radiological parameters
Final infarct volume 2 (0–10) 10 (3–26) 60 (20–135) 0.000
Malignant MCA infarct, no. (%) 0 (0) 1 (1) 22 (20) 0.000
PH 1 or 2, no. (%) 2 (2) 4 (4) 16 (14) 0.001
*Excellent outcome (mRS 0 to 1) versus mRS 2.
IQR indicates interquartile range; IVT, intravenous thrombolysis; EVT, endovascular thrombolysis.
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as a mRS score of 0 to 1 at Day 90. The study was approved by a
local ethics committee.
Statistical Analysis
Continuous variables are reported as the meanSD or median with
interquartile ranges and were compared with the Student t test, 1-way
analysis of variance, Mann–Whitney, or Kruskal-Wallis tests as
appropriate. Correlations were assessed with Pearson or Spearman
coefficients, and categorical variables were compared with the 2
and Fisher exact tests. Binary and ordinal multivariate logistic
regression models were used to assess the effects of UA levels on
clinical outcome adjusted for variables showing a P0.2 in univar-
iate analysis. In binary logistic regression models, mRS was dichot-
omized (mRS2 versus mRS2) and a backward stepwise strategy
was used to select the variables remaining in the final model. Age,
sex, time to treatment, and treatment modality were forced to remain
in the final model. We also constructed ordinal regression models to
show the results were consistent across levels of the mRS (3
categories: 0 to 1, 2 to 3, 4 to 6) adjusted for factors and covariates
related to dichotomized mRS in the binary analysis. Infarct volume
was assessed in multiple regression adjusted for age, sex, and
baseline NIHSS score. The analysis was performed using PASW
Statistics Version 18.0 and the level of significance was established
at the 0.05 level (2-sided).
Results
Main Characteristics of the Study Population
In the study population, mean (SD) age was 72 (12.2) years,
56% of patients were males, median (interquartile range)
NIHSS score on admission was 11 (6 to 18) median (inter-
quartile range) delay to thrombolytic treatment was 135 (105
to 172) minutes, and mean (SD) UA levels were 5.5 (1.70).
Expectedly, males had higher levels of UA than females, 5.9
(1.60) versus 5.1 (1.72; P0.001), as well as patients with
history of hypertension, 5.8 (1.66) versus 5.1 (1.67; P0.01)
or diabetes, 6.0 (1.77), versus 5.4 (1.65; P0.05). Age,
coronary artery disease, alcohol, smoking, history of prior
stroke, or stroke subtype did not significantly modify UA
levels (data not shown). Excellent outcome was achieved by
101 (32%) patients at Day 90. Moreover, 52 (16%) patients
reached a mRS of 2, 51 (16%) patients a mRS of 3, 61 (19%)
patients a mRS of 4, 16 (5%) a mRS of 5, and 36 (11%)
patients a mRS of 6.
Clinical Course and Functional Outcome in
Relation to UA Levels
In the whole study group, there was an inverse correlation
between the levels of UA and the severity of stroke (NIHSS
score) at baseline (r0.16, P0.006), at 24 hours
(r0.24, P0.001), at hospital discharge (r0.26,
P0.001), and at Day 90 (r0.18, P0.001) and with
mRS score at Day 90 (r0.14, P0.013). As shown in
Table 1, outcome was associated with male sex; younger age;
absent history of stroke, diabetes, or prestroke disability;
atrial fibrillation; and baseline NIHSS score. Moreover, UA
levels were significantly higher in patients with excellent
outcome than in patients with poor outcome, 5.82 (1.39)
versus 5.42 (1.81; P0.029). As shown in Table 2, increasing
UA levels (OR, 1.23; 95% CI, 1.03 to 1.49; P0.025) were
associated with excellent outcome at 90 days in adjusted
models. In ordinal regression analyses, higher UA levels also
increased the risk of shifting to a better category across the
mRS scale (OR, 1.19; 95% CI, 1.04 to 1.38; P0.014).
UA Levels and CT Scan Findings
Expectedly, patients with a poor outcome had larger infarc-
tions than patients with an excellent outcome, 24.4 mL (6.00
to 76.72 mL) versus 1.9 mL (0 to 9.97 mL; P0.001). The
levels of UA and the volume of final infarction were inversely
correlated (r0.216, P0.001) and the inverse correlation
remained after adjustment for age, sex, and baseline NIHSS
score (t value2.54, P0.01). Higher UA levels remained
associated with smaller lesions in analyses restricted to
patients (n234) with MCA infarction (t value2.09,
P0.04). Moreover, significantly lower UA levels were
found in patients with malignant MCA infarction (n23;
4.721.84 versus 5.611.67 mg/dL, P0.015) and in pa-
tients with PH 1 or 2 (n22; 4.622.16 versus 5.621.64,
P0.008), as shown in the Figure. As shown in Table 1, both
malignant MCA infarction and PH 1 or 2 were associated
with bad outcomes.
Discussion
In this study aimed to analyze the relationship between serum
UA levels and outcome in patients treated with thrombolysis,
we found that higher UA levels were associated with an
increased rate of excellent recovery independently of baseline
variables. Moreover, increased serum levels of UA were
significantly associated with smaller infarction volumes and
lower rates of malignant MCA infarctions or PH (1 or 2)
postthrombolysis. Overall, these results support the study of
the exogenous administration of UA in patients with acute
stroke who receive thrombolytic therapy.
Table 2. Excellent Clinical Outcome (mRS 0 to 1) and mRS
Categorized in 3 Levels (0 to 1, 2 to 3, 4 to 6) at 3 Months in
Relation to UA Levels
Excellent Outcome
mRS 0 to 1 Versus 2 to 6
OR* (95% CI) P
Ordinal Assessment
mRS 0 to 1 Versus
2 to 3 Versus 4 to 6
OR* (95% CI) P
UA, mg/dL 1.23 (1.03–1.49) P0.025 1.19 (1.04–1.38) P0.014
Baseline NIHSS
score (IQR)
0.40 (0–30–0–54) P0.001 0.38 (0.30–0.48) P0.001
Age per 10 years 0.80 (0.62–1.02) P0.069 0.77 (0.63–0.95) P0.016
Prior mRS per
unit
0.44 (0.30–0.63) P0.001 0.55 (0.43–0.71) P0.001
Prior stroke, yes
versus no









1.38 (0.55–3.48) P0.498 0.83 (0.40–1.72) P0.616
Sex, male
versus female
1.64 (0.85–3.15) P0.141 1.18 (0.71–1.96) P0.513
*Binary or ordinal logistic regression (LR) estimates as appropriate. The OR
indicates the risk of obtaining an excellent outcome (binary LR) or the risk of
shifting to a better category in the ordered 3-category mRS scale (ordinal LR).
IQR indicates interquartile range; IVT, intravenous thrombolysis; EVT, endo-
vascular thrombolysis.
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UA is the most important endogenous antioxidant in the
human brain and it has shown neuroprotective effects in
preclinical studies.4,5 The safety and feasibility of UA mod-
ulation was recently assessed in 2 small randomized con-
trolled trials that decreased18 or increased19 the levels of this
natural antioxidant in patients with acute stroke. In the former
study,18 patients received allopurinol within 72 hours of
stroke onset and did not experience safety concerns. In the
latter, allopurinol was able to reduce the levels of UA and of
proinflammatory intercellular adhesion molecule-1,18 but the
study did not establish if allopurinol was beneficial or
whether the observed changes in inflammatory markers were
the result of xanthine oxidation inhibition20 or UA reduction.
In a recent pilot study,19 patients with stroke were treated with
alteplase and then randomized to receive UA or placebo.
Active treatment with UA prevented an early fall of endog-
enous UA levels and treated patients experienced no serious
adverse events, disclosed lower levels of lipid peroxidation,19
and had less activation of active matrix metalloproteinase-921
compared with control subjects. It was argued that UA had
impeded oxidation and/or nitrosylation of matrix metallopro-
teinases after brain ischemia22 and modulated essential redox-
sensitive transcription factors that promote inflammation.23
In agreement with previous clinical11 and radiological15
observations, the current study found an inverse correlation
between the levels of UA and the volume of the infarction at
follow-up brain CT scan, and this finding was confirmed in
sensitive analyses restricted to patients with MCA territory
infarctions. On the contrary, lower UA levels were associated
with a greater incidence of malignant MCA infarctions and
hemorrhagic transformation (PH 1 or 2). Although the early
assessment of infarction size on CT scan may have underes-
timated the final volume of the infarctions, all CT scans were
performed at a similar time delay (2412 hours) after stroke
onset and were evaluated by investigators blinded to clinical
and laboratory findings to limit the risk of bias.
The current study is limited by the lack of information
regarding the rate and timing of arterial reperfusion and also
because UA was measured only once. Hence, it could be argued
that inconsistent recanalization rates between the UA groups did
influence the rate of recovery or that lower UA levels were the
result of larger infarctions. Nonetheless, experiments conducted
after transient focal brain ischemia in rats demonstrated that the
administration of UA and alteplase resulted in synergic neuro-
protective effects.5 The associations observed in the current
study among higher UA levels, better clinical outcome, smaller
infarctions, and less bleeding complications at follow-up do not
prove causality but strongly suggest that the endogenous levels
of UA are of major biological relevance in patients with stroke
receiving thrombolytic therapy. These results deserve confirma-
tion in larger prospective studies.
Conclusions
Overall, the results of the current study give additional
support to the clinical significance of oxidative stress in
patients with acute stroke and open new therapeutic avenues
aimed to increase the benefits of thrombolytic therapy. One
such approach is the dual administration of exogenous UA
and alteplase, a strategy recently proven to be feasible and
safe.19 However, the definitive proof of causality between
increased UA levels and better stroke outcome requires an
appropriately designed therapeutic controlled trial.24 For this
reason, the Spanish Drugs Agency has recently approved a
multicenter clinical trial of UA administration in patients with
acute stroke treated with alteplase and which is due to start in
2010 (EudraCT 2007-002687-95 and NCT00860366).
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